{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:42:50Z","timestamp":1793248970916,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European Community's Seventh Framework Programme","award":["602391"],"award-info":[{"award-number":["602391"]}]},{"name":"Polish Ministerial funds for science"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ejpn-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejpn.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T05:32:12Z","timestamp":1527139932000},"page":"738-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations"],"prefix":"10.1016","volume":"22","author":[{"given":"Paolo","family":"Curatolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Lagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Aronica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e8 Carlos","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kotulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Moavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finbar","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-7954","authenticated-orcid":false,"given":"Antigone","family":"Papavasiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tzadok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2018.05.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/9820181","article-title":"Recent advances and challenges of mTOR inhibitors use in treatment of patients with tuberous sclerosis complex","volume":"9820181","author":"Palavra","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ejpn.2018.05.006_bib2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","article-title":"TuberOus SClerosis registry to increase disease awareness (TOSCA) \u2212 baseline data on 2093 patients","volume":"12","author":"Kingswood","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ejpn.2018.05.006_bib5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4040","article-title":"Presentation and diagnosis of tuberous sclerosis complex in infants","volume":"140","author":"Davis","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2018.05.006_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/adc.2003.026815","article-title":"The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex","volume":"89","author":"O'Callaghan","year":"2004","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ejpn.2018.05.006_bib8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.yebeh.2008.07.010","article-title":"Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients","volume":"13","author":"Staley","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/01.wnl.0000250330.44291.54","article-title":"Cognitive prognosis of patients with tuberous sclerosis complex","volume":"68","author":"Winterkorn","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2018.05.006_bib10","first-page":"6","article-title":"New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)","author":"Gipson","year":"2017","journal-title":"F1000 Res."},{"key":"10.1016\/j.ejpn.2018.05.006_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","volume":"70","author":"Capal","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.yebeh.2011.08.037","article-title":"Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis","volume":"22","author":"Cusmai","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"9 Suppl 5","key":"10.1016\/j.ejpn.2018.05.006_bib15","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/WNL.59.9_suppl_5.S7","article-title":"Animal models of epilepsy","volume":"59","author":"White","year":"2002","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.ejpn.2018.05.006_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1167.2010.02602.x","article-title":"Therapeutic approaches to epileptogenesis\u2212hope on the horizon","volume":"51","author":"Pitk\u00e4nen","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13311-014-0257-2","article-title":"Past and present definitions of epileptogenesis and its biomarkers","volume":"11","author":"Pitk\u00e4nen","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejpn.2018.05.006_bib18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022822","article-title":"Epileptogenesis","volume":"5","author":"Pitk\u00e4nen","year":"2015","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.ejpn.2018.05.006_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coph.2017.07.012","article-title":"Epileptogenesis meets Occam's razor","volume":"35","author":"Slovatir","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpn.2015.12.005","article-title":"Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC","volume":"20","author":"Curatolo","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejpn.2013.12.006","article-title":"EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients. A prospective study of 5 patients","volume":"18","author":"Domanska-Pakiela","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2015.09.013","article-title":"Clinical encephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants","volume":"54","author":"Wu","year":"2016","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib23","unstructured":"Potential EEG biomarkers and antiepileptogenic strategies for epilepsy in TSC.Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01767779?term=epilepsy&cond=tuberous+sclerosis&rank=4. Last accessed: May 30, 2018."},{"key":"10.1016\/j.ejpn.2018.05.006_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13023-018-0764-z","article-title":"Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?","volume":"13","author":"Slowi\u0144ska","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ejpn.2018.05.006_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2017.05.014","article-title":"Early detection of tuberous sclerosis complex: an opportunity for improved neurodevelopmental outcome","volume":"76","author":"Chung","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pediatrneurol.2017.04.009","article-title":"The utility of surveillance electroencephalography to guide early antiepileptic drug therapy in infants with tuberous sclerosis complex","volume":"72","author":"Whitney","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1542\/peds.2010-0192","article-title":"Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs","volume":"127","author":"Staley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2018.05.006_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ejpn.2018.05.006_bib30","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2018.05.006_bib31","unstructured":"EPISTOP. Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy \u2013 tuberous sclerosis complex. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02098759?term=epistop&cond=tuberous+sclerosis+complex&rank=1. Last accessed: May 30, 2018."},{"key":"10.1016\/j.ejpn.2018.05.006_bib32","unstructured":"PREVeNT. Preventing epilepsy using vigabatrin in infants with tuberous sclerosis complex. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02849457?term=prevent+and+tsc&rank=1. Last accessed: May 30, 2018."},{"issue":"Suppl 1","key":"10.1016\/j.ejpn.2018.05.006_bib33","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ejpn.2017.04.1142","article-title":"Prospective serial neuropsychological study in infants with tuberous sclerosis complex (TSC): first Analysis from the EPISTOP Project","volume":"21","author":"Benvenuto","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs","volume":"56","author":"Overwater","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dmcn.12573","article-title":"Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study","volume":"57","author":"Riikonen","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2016.01.012","article-title":"A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: the UCLA experience","volume":"57","author":"Schwarz","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1528-1167.2008.01788.x","article-title":"Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG","volume":"50","author":"Muzykewicz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40272-016-0188-y","article-title":"Improving outcomes in infantile spasms","volume":"18","author":"Iyer","year":"2016","journal-title":"Paediatr Drugs."},{"key":"10.1016\/j.ejpn.2018.05.006_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.ejpn.2018.05.006_bib40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/JAMMR\/2017\/36585","article-title":"Survey report on parents and patients related to the use of cannabidiol symptomatic epilepsy secondary to tuberous sclerosis complex (TSC) in Mexico","volume":"23","author":"Aguirre-Vel\u00e1zquez","year":"2017","journal-title":"J Adv Med Med Res"},{"key":"10.1016\/j.ejpn.2018.05.006_bib42","unstructured":"GWP42003-P, CBD. A randomized controlled trial of cannabidiol for seizures in tuberous sclerosis complex. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02544763?term=epilepsy&cond=tuberous+sclerosis&rank=13. Last accessed: May 30, 2018."},{"key":"10.1016\/j.ejpn.2018.05.006_bib43","unstructured":"GWPCARE6. An open-label extension trial of cannabidiol (GWP42003-P, CBD) for seizures in tuberous sclerosis complex. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02544750?term=epilepsy&cond=tuberous+sclerosis&rank=14. Last accessed: May 30, 2018."},{"key":"10.1016\/j.ejpn.2018.05.006_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2016.81","article-title":"The mTOR signalling cascade: paving new roads to cure neurological disease","volume":"12","author":"Crino","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","article-title":"Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy","volume":"52","author":"Curatolo","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib46","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2018.05.006_bib49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","article-title":"Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial","volume":"87","author":"Overwater","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2018.05.006_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of everolimus in children with TSC-associated epilepsy \u2013 pilot data from an open single-center prospective study","volume":"11","author":"Samueli","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ejpn.2018.05.006_bib51","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2018.05.006_bib52","series-title":"Sustained reduction in seizure frequency with adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex (TSC) in children under 6 years of age: an analysis of the randomized EXIST-3 study","author":"Curatolo","year":"2018"},{"key":"10.1016\/j.ejpn.2018.05.006_bib53","unstructured":"A pilot study to evaluate the effects of everolimus on brain mTOR activity and cortical hyperexcitability in TSC and FCD. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02451696?term=epilepsy&cond=tuberous+sclerosis&rank=7. Last accessed: May 30, 2018."},{"key":"10.1016\/j.ejpn.2018.05.006_bib54","unstructured":"European Medicines Agency. Votubia (everolimus): summary of opinion. December 15, 2016. Available at: ema.europa.eu."},{"issue":"1","key":"10.1016\/j.ejpn.2018.05.006_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpn.2017.07.018","article-title":"Dramatic relapse of seizures after everolimus withdrawal","volume":"22","author":"Mingarelli","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1824-7288-39-57","article-title":"Is mTOR inhibition a systemic treatment for tuberous sclerosis?","volume":"39","author":"Moavero","year":"2013","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.ejpn.2018.05.006_bib57","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib58","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1528-1167.2006.00569.x","article-title":"Proposed criteria for referral and evaluation of children for epilepsy surgery: recommendations of the Subcommission for Pediatric Epilepsy Surgery","volume":"47","author":"Cross","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib59","first-page":"150","article-title":"Epilepsy surgery in tuberous sclerosis complex: in pursuit of the epileptogenic center(s)","volume":"17","author":"Gupta","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1212\/WNL.0b013e3181ce5d9e","article-title":"Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex","volume":"74","author":"Wu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2018.05.006_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3171\/2014.10.PEDS14107","article-title":"Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions","volume":"15","author":"Arya","year":"2015","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.ejpn.2018.05.006_bib62","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.seizure.2007.03.001","article-title":"Epilepsy surgery in tuberous sclerosis: the Dutch experience","volume":"16","author":"Jansen","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2018.05.006_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053565","article-title":"Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis","volume":"8","author":"Fallah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpn.2018.05.006_bib64","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eplepsyres.2013.02.016","article-title":"Predictors of seizure freedom after surgical management of tuberous sclerosis complex: a systematic review and meta-analysis","volume":"105","author":"Zhang","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ejpn.2018.05.006_bib65","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1227\/NEU.0000000000000875","article-title":"Resective epilepsy surgery for tuberous sclerosis in children: determining predictors of seizure outcomes in a multicenter retrospective cohort study","volume":"77","author":"Fallah","year":"2015","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejpn.2018.05.006_bib66","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s00415-017-8507-y","article-title":"Long-term outcomes of epilepsy surgery in tuberous sclerosis complex","volume":"264","author":"Liang","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib67","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/j.1528-1167.2011.02981.x","article-title":"The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway","volume":"52","author":"McDaniel","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14581\/jer.17008","article-title":"Ketogenic diet for the management of epilepsy associated with tuberous sclerosis complex in children","volume":"7","author":"Park","year":"2017","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.ejpn.2018.05.006_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yebeh.2015.03.003","article-title":"The ketogenic diet can be used successfully with corticosteroids for epileptic encephalopathies","volume":"48","author":"Ville","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.yebeh.2008.04.001","article-title":"Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex","volume":"13","author":"Major","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib71","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.yebeh.2009.08.018","article-title":"Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery","volume":"16","author":"Elliott","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0887-8994(01)00312-5","article-title":"Vagal nerve stimulation in tuberous sclerosis patients","volume":"25","author":"Parain","year":"2001","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2010.03.003","article-title":"Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis","volume":"43","author":"Zamponi","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.05.006_bib74","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/epi.12762","article-title":"Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children","volume":"55","author":"Orosz","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2018.05.006_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yebeh.2016.07.034","article-title":"Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex","volume":"63","author":"Fallah","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2018.05.006_bib76","unstructured":"A pilot study to evaluate the effects of everolimus on brain mTOR activity and cortical hyperexcitability in TSC and FCD. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02451696?term=seizures&cond=tsc&draw=2&rank=12. Last accessed: April 10, 2018."},{"key":"10.1016\/j.ejpn.2018.05.006_bib77","unstructured":"Application of novel diagnostic and therapeutical methods in epilepsy and neurodevelopmental abnormalities in children (EPIMARKER). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486366?term=seizures&cond=tsc&draw=3&rank=17. Last accessed: April 10, 2018."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379817320573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379817320573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T23:43:13Z","timestamp":1536622993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379817320573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1090379817320573"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2018.05.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}